{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:56Z","timestamp":1791676136182,"version":"4.3.4"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07142-6","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:35:34Z","timestamp":1784900134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining and managing high-risk acute myeloid leukemia (AML) in 2026"],"prefix":"10.1007","volume":"105","author":[{"given":"Mohamed Nazem","family":"Alibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem Ahmad","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Nassir","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad Saeed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"12","key":"7142_CR1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152","journal-title":"N Engl J Med"},{"issue":"23","key":"7142_CR2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"issue":"18","key":"7142_CR3","first-page":"4179","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood J Am Soc Hematol 113(18):4179\u20134187","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"7142_CR4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol 100(5):860\u2013891","journal-title":"Am J Hematol"},{"issue":"12","key":"7142_CR5","first-page":"1345","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood J Am Soc Hematol 140(12):1345\u20131377","journal-title":"Blood J Am Soc Hematol"},{"key":"7142_CR6","doi-asserted-by":"crossref","unstructured":"Li W (2022) The 5th edition of the World Health Organization classification of hematolymphoid tumors. Exon, pp 1\u201321","DOI":"10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors"},{"issue":"4","key":"7142_CR7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022226","volume":"143","author":"KD Sahasrabudhe","year":"2024","unstructured":"Sahasrabudhe KD, Mims AS (2024) MRD in AML: who, what, when, where, and how? Blood 143(4):296\u2013298","journal-title":"Blood"},{"key":"7142_CR8","doi-asserted-by":"crossref","unstructured":"Cloos J et al (2025) 2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood","DOI":"10.1182\/blood.2025031480"},{"issue":"1","key":"7142_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41408-024-01140-5","volume":"14","author":"S Gross","year":"2024","unstructured":"Gross S et al (2024) Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy. Blood cancer J 14(1):160","journal-title":"Blood cancer J"},{"issue":"15","key":"7142_CR10","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood.2022018108","volume":"141","author":"J Othman","year":"2023","unstructured":"Othman J et al (2023) Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood 141(15):1846\u20131857","journal-title":"Blood"},{"issue":"9","key":"7142_CR11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/s41375-023-01985-y","volume":"37","author":"MJ Hochman","year":"2023","unstructured":"Hochman MJ et al (2023) Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification. Leukemia 37(9):1915\u20131918","journal-title":"Leukemia"},{"issue":"21","key":"7142_CR12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169\u20132173","journal-title":"Blood"},{"issue":"4","key":"7142_CR13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW et al (2024) Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99(4):615\u2013624","journal-title":"Am J Hematol"},{"issue":"11","key":"7142_CR14","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1038\/s41375-025-02730-3","volume":"39","author":"A Venditti","year":"2025","unstructured":"Venditti A et al (2025) Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia 39(11):2697\u20132707","journal-title":"Leukemia"},{"issue":"6","key":"7142_CR15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3324\/haematol.2024.286589","volume":"110","author":"C Jim\u00e9nez-Vicente","year":"2025","unstructured":"Jim\u00e9nez-Vicente C et al (2025) Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. Haematologica 110(6):1402\u20131406","journal-title":"Haematologica"},{"issue":"7","key":"7142_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nm.4125","volume":"22","author":"S Li","year":"2016","unstructured":"Li S et al (2016) Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med 22(7):792\u2013799","journal-title":"Nat Med"},{"issue":"7540","key":"7142_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518(7540):552\u2013555","journal-title":"Nature"},{"issue":"7382","key":"7142_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L et al (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382):506\u2013510","journal-title":"Nature"},{"issue":"7661","key":"7142_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush LI et al (2017) Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547(7661):104\u2013108","journal-title":"Nature"},{"issue":"1","key":"7142_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1369\/00221554211062499","volume":"70","author":"RJ Molenaar","year":"2022","unstructured":"Molenaar RJ, Wilmink JW (2022) IDH1\/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy. J Histochem Cytochem 70(1):83\u201397","journal-title":"J Histochem Cytochem"},{"issue":"9","key":"7142_CR21","first-page":"2114","volume":"119","author":"FG R\u00fccker","year":"2012","unstructured":"R\u00fccker FG et al (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. J Am Soc Hematol 119(9):2114\u20132121","journal-title":"J Am Soc Hematol"},{"issue":"29","key":"7142_CR22","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","volume":"37","author":"L Angenendt","year":"2019","unstructured":"Angenendt L et al (2019) Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts. J Clin Oncol 37(29):2632\u20132642","journal-title":"J Clin Oncol"},{"issue":"1","key":"7142_CR23","first-page":"100","volume":"122","author":"J Kr\u00f6nke","year":"2013","unstructured":"Kr\u00f6nke J et al (2013) Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood J Am Soc Hematol 122(1):100\u2013108","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"7142_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N et al (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2):299\u2013312","journal-title":"Leukemia"},{"issue":"33","key":"7142_CR25","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2009.22.2547","volume":"27","author":"AV Rao","year":"2009","unstructured":"Rao AV et al (2009) Age-specific differences in oncogenic pathway dysregulation in patients with acute myeloid leukemia. J Clin Oncol 27(33):5580\u20135586","journal-title":"J Clin Oncol"},{"issue":"1","key":"7142_CR26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM et al (2025) Acute myeloid leukemia management and research in 2025. Cancer J Clin 75(1):46\u201367","journal-title":"Cancer J Clin"},{"issue":"1","key":"7142_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-016-0337-3","volume":"9","author":"J Xu","year":"2016","unstructured":"Xu J et al (2016) DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1. J Hematol Oncol 9(1):106","journal-title":"J Hematol Oncol"},{"issue":"7488","key":"7142_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush LI et al (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506(7488):328\u2013333","journal-title":"Nature"},{"issue":"9","key":"7142_CR29","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/leu.2014.124","volume":"28","author":"A Im","year":"2014","unstructured":"Im A et al (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28(9):1774\u20131783","journal-title":"Leukemia"},{"issue":"2","key":"7142_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41375-021-01368-1","volume":"36","author":"LV Cappelli","year":"2022","unstructured":"Cappelli LV et al (2022) Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. Leukemia 36(2):394\u2013402","journal-title":"Leukemia"},{"issue":"4","key":"7142_CR31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3324\/haematol.2019.235150","volume":"106","author":"T D\u2019Altri","year":"2020","unstructured":"D\u2019Altri T et al (2020) The ASXL1-G643Wvariant accelerates the development of CEBPA mutant acute myeloid leukemia. Haematologica 106(4):1000","journal-title":"Haematologica"},{"issue":"3","key":"7142_CR32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2015.11.011","volume":"44","author":"D Inoue","year":"2016","unstructured":"Inoue D et al (2016) Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Exp Hematol 44(3):172\u2013176e1","journal-title":"Exp Hematol"},{"issue":"2","key":"7142_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM et al (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21(2):178\u2013184","journal-title":"Nat Med"},{"issue":"1","key":"7142_CR34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17\u201330","journal-title":"Cancer Cell"},{"key":"7142_CR35","doi-asserted-by":"crossref","unstructured":"Yu H et al (2025) The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia: transcriptional control and signal transduction, cell cycle. Leukemia 39(10):2329\u20132339","DOI":"10.1038\/s41375-025-02657-9"},{"issue":"22","key":"7142_CR36","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.3390\/ijms21228505","volume":"21","author":"C Gurnari","year":"2020","unstructured":"Gurnari C, Pagliuca S, Visconte V (2020) Deciphering the therapeutic resistance in acute myeloid leukemia. Int J Mol Sci 21(22):8505","journal-title":"Int J Mol Sci"},{"key":"7142_CR37","doi-asserted-by":"crossref","first-page":"e93019","DOI":"10.7554\/eLife.93019","volume":"13","author":"K Nuno","year":"2024","unstructured":"Nuno K et al (2024) Convergent epigenetic evolution drives relapse in acute myeloid leukemia. Elife 13:e93019","journal-title":"Elife"},{"key":"7142_CR38","doi-asserted-by":"crossref","first-page":"204062072413065","DOI":"10.1177\/20406207241306553","volume":"15","author":"MA Akbarzadeh","year":"2024","unstructured":"Akbarzadeh MA, Vaez-Gharamaleki Y, Hosseini M-S (2024) Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia. Therapeutic Adv Hematol 15:20406207241306553","journal-title":"Therapeutic Adv Hematol"},{"issue":"1","key":"7142_CR39","first-page":"42","volume":"127","author":"BJ Wouters","year":"2016","unstructured":"Wouters BJ, Delwel R (2016) Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. J Am Soc Hematol 127(1):42\u201352","journal-title":"J Am Soc Hematol"},{"issue":"14","key":"7142_CR40","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.7150\/thno.53170","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang Y et al (2021) Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2. Theranostics 11(14):6891","journal-title":"Theranostics"},{"issue":"5","key":"7142_CR41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"MY Konopleva","year":"2011","unstructured":"Konopleva MY, Jordan CT (2011) Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 29(5):591\u2013599","journal-title":"J Clin Oncol"},{"issue":"5","key":"7142_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S M\u00e9ndez-Ferrer","year":"2020","unstructured":"M\u00e9ndez-Ferrer S et al (2020) Bone marrow niches in haematological malignancies. Nat Rev Cancer 20(5):285\u2013298","journal-title":"Nat Rev Cancer"},{"issue":"4\u20135","key":"7142_CR43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","volume":"12","author":"M Konopleva","year":"2009","unstructured":"Konopleva M et al (2009) Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updates 12(4\u20135):103\u2013113","journal-title":"Drug Resist Updates"},{"issue":"9","key":"7142_CR44","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI7615","volume":"104","author":"A Peled","year":"1999","unstructured":"Peled A et al (1999) The chemokine SDF-1 stimulates integrin-mediated arrest of CD34\u2009+\u2009cells on vascular endothelium under shear flow. J Clin Investig 104(9):1199\u20131211","journal-title":"J Clin Investig"},{"issue":"17","key":"7142_CR45","first-page":"2691","volume":"123","author":"R Jacamo","year":"2014","unstructured":"Jacamo R et al (2014) Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-\u03baB mediates chemoresistance. Blood. J Am Soc Hematol 123(17):2691\u20132702","journal-title":"J Am Soc Hematol"},{"issue":"4","key":"7142_CR46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.7314\/APJCP.2014.15.4.1823","volume":"15","author":"K Song","year":"2014","unstructured":"Song K et al (2014) HIF-1\u03b1 and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac J Cancer Prev 15(4):1823\u20131829","journal-title":"Asian Pac J Cancer Prev"},{"issue":"24","key":"7142_CR47","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ et al (2018) Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med 379(24):2330\u20132341","journal-title":"N Engl J Med"},{"key":"7142_CR48","doi-asserted-by":"crossref","unstructured":"Garrido F (2019) MHC\/HLA class I loss in cancer cells. MHC class-I loss and cancer immune escape, : 15\u201378","DOI":"10.1007\/978-3-030-17864-2_2"},{"issue":"1","key":"7142_CR49","doi-asserted-by":"crossref","first-page":"101247","DOI":"10.1016\/j.beha.2021.101247","volume":"34","author":"N Daver","year":"2021","unstructured":"Daver N (2021) Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol 34(1):101247","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"7142_CR50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA et al (2024) Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Reviews Clin Oncol 21(2):147\u2013164","journal-title":"Nat Reviews Clin Oncol"},{"issue":"10","key":"7142_CR51","first-page":"1039","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A (2019) The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood J Am Soc Hematol 133(10):1039\u20131048","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"7142_CR52","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F et al (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25(11):1315\u20131321","journal-title":"Nat Biotechnol"},{"issue":"3","key":"7142_CR53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED et al (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12(3):329\u2013341","journal-title":"Cell Stem Cell"},{"issue":"11","key":"7142_CR54","first-page":"1200","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood J Am Soc Hematol 140(11):1200\u20131228","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"7142_CR55","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"11","key":"7142_CR56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","volume":"147","author":"J Cloos","year":"2026","unstructured":"Cloos J et al (2026) 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood 147(11):1147\u20131167","journal-title":"Blood"},{"issue":"12","key":"7142_CR57","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ et al (2020) Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"5","key":"7142_CR58","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/S2352-3026(25)00037-7","volume":"12","author":"N Potter","year":"2025","unstructured":"Potter N et al (2025) Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. Lancet Haematol 12(5):e346\u2013e356","journal-title":"Lancet Haematol"},{"issue":"13","key":"7142_CR59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M et al (2018) Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med 378(13):1189\u20131199","journal-title":"N Engl J Med"},{"issue":"26","key":"7142_CR60","first-page":"2753","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M et al (2021) Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. J Am Soc Hematol 138(26):2753\u20132767","journal-title":"J Am Soc Hematol"},{"issue":"12","key":"7142_CR61","first-page":"1275","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. J Am Soc Hematol 131(12):1275\u20131291","journal-title":"J Am Soc Hematol"},{"key":"7142_CR62","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2023-181709","volume":"142","author":"LL Ngai","year":"2023","unstructured":"Ngai LL et al (2023) The Laip-based-Dfn approach is superior in terms of useful MRD results as compared to the Laip approach after cycle II in acute myeloid leukemia. Blood 142:1572","journal-title":"Blood"},{"issue":"1","key":"7142_CR63","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","volume":"93","author":"BL Wood","year":"2020","unstructured":"Wood BL (2020) Acute myeloid leukemia minimal residual disease detection: the difference from normal approach. Curr Protocols Cytometry 93(1):e73","journal-title":"Curr Protocols Cytometry"},{"issue":"15","key":"7142_CR64","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","volume":"36","author":"SD Freeman","year":"2018","unstructured":"Freeman SD et al (2018) Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol 36(15):1486\u20131497","journal-title":"J Clin Oncol"},{"issue":"32","key":"7142_CR65","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman SD et al (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 31(32):4123\u20134131","journal-title":"J Clin Oncol"},{"issue":"31","key":"7142_CR66","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn M et al (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol 31(31):3889\u20133897","journal-title":"J Clin Oncol"},{"issue":"10","key":"7142_CR67","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","volume":"20","author":"F Buccisano","year":"2006","unstructured":"Buccisano F et al (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20(10):1783\u20131789","journal-title":"Leukemia"},{"key":"7142_CR68","doi-asserted-by":"crossref","unstructured":"Short NJ et al (2022) Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97:E408\u2013E411","DOI":"10.1002\/ajh.26698"},{"issue":"14","key":"7142_CR69","first-page":"2826","volume":"120","author":"JAL Yin","year":"2012","unstructured":"Yin JAL et al (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. J Am Soc Hematol 120(14):2826\u20132835","journal-title":"J Am Soc Hematol"},{"issue":"3","key":"7142_CR70","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2015.131946","volume":"101","author":"C Willekens","year":"2016","unstructured":"Willekens C et al (2016) Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica 101(3):328","journal-title":"Haematologica"},{"issue":"10","key":"7142_CR71","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/s41375-018-0086-0","volume":"32","author":"A H\u00f6llein","year":"2018","unstructured":"H\u00f6llein A et al (2018) Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. Leukemia 32(10):2270\u20132274","journal-title":"Leukemia"},{"issue":"19","key":"7142_CR72","first-page":"1608","volume":"134","author":"FG R\u00fccker","year":"2019","unstructured":"R\u00fccker FG et al (2019) Measurable residual disease monitoring in acute myeloid leukemia with t (8; 21)(q22; q22. 1): results from the AML Study Group. Blood. J Am Soc Hematol 134(19):1608\u20131618","journal-title":"J Am Soc Hematol"},{"issue":"12","key":"7142_CR73","first-page":"1880","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y et al (2014) In adults with t (8; 21) AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood J Am Soc Hematol 124(12):1880\u20131886","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"7142_CR74","doi-asserted-by":"crossref","first-page":"e35717","DOI":"10.1002\/cncr.35717","volume":"131","author":"L Wang","year":"2025","unstructured":"Wang L et al (2025) Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia. Cancer 131(2):e35717","journal-title":"Cancer"},{"issue":"16","key":"7142_CR75","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE et al (2023) Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-M\u00fcnster Study Group. J Clin Oncol 41(16):2963\u20132974","journal-title":"J Clin Oncol"},{"issue":"24","key":"7142_CR76","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood.2024026605","volume":"144","author":"S Loo","year":"2024","unstructured":"Loo S et al (2024) Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia. Blood 144(24):2554\u20132557","journal-title":"Blood"},{"issue":"Supplement 1","key":"7142_CR77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2024-202895","volume":"144","author":"S Loo","year":"2024","unstructured":"Loo S et al (2024) Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial. Blood 144(Supplement 1):223\u2013223","journal-title":"Blood"},{"issue":"Supplement 1","key":"7142_CR78","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2022-167837","volume":"140","author":"AH Wei","year":"2022","unstructured":"Wei AH et al (2022) ALLG AMLM26 Phase 1B\/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial. Blood 140(Supplement 1):3341\u20133343","journal-title":"Blood"},{"key":"7142_CR79","doi-asserted-by":"crossref","unstructured":"Dillon LW et al (2024) Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia. JAMA Oncol 10(8):1104\u20131110","DOI":"10.1001\/jamaoncol.2024.0985"},{"issue":"4","key":"7142_CR80","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T et al (2023) Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol 41(4):756\u2013765","journal-title":"J Clin Oncol"},{"issue":"22","key":"7142_CR81","first-page":"2407","volume":"140","author":"S Loo","year":"2022","unstructured":"Loo S et al (2022) Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood J Am Soc Hematol 140(22):2407\u20132411","journal-title":"Blood J Am Soc Hematol"},{"issue":"16","key":"7142_CR82","first-page":"1703","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. J Am Soc Hematol 132(16):1703\u20131713","journal-title":"J Am Soc Hematol"},{"issue":"10","key":"7142_CR83","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","volume":"5","author":"C-H Tsai","year":"2021","unstructured":"Tsai C-H et al (2021) Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv 5(10):2456\u20132466","journal-title":"Blood Adv"},{"issue":"6","key":"7142_CR84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","volume":"11","author":"H-J Kim","year":"2021","unstructured":"Kim H-J et al (2021) Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood cancer J 11(6):109","journal-title":"Blood cancer J"},{"issue":"22","key":"7142_CR85","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D et al (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27(22):3650\u20133658","journal-title":"J Clin Oncol"},{"issue":"11","key":"7142_CR86","first-page":"1694","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G et al (2022) Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. J Am Soc Hematol 139(11):1694\u20131706","journal-title":"J Am Soc Hematol"},{"issue":"9","key":"7142_CR87","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH et al (2018) Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol 93(9):1142\u20131152","journal-title":"Am J Hematol"},{"issue":"12","key":"7142_CR88","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS et al (2020) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol 38(12):1273\u20131283","journal-title":"J Clin Oncol"},{"issue":"13","key":"7142_CR89","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249\u20131259","journal-title":"N Engl J Med"},{"issue":"13","key":"7142_CR90","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361(13):1235\u20131248","journal-title":"N Engl J Med"},{"issue":"27","key":"7142_CR91","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 31(27):3360\u20133368","journal-title":"J Clin Oncol"},{"issue":"8","key":"7142_CR92","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM et al (2021) Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552\u2013e561","journal-title":"Lancet Haematol"},{"issue":"4","key":"7142_CR93","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","volume":"39","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD et al (2025) Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854\u2013863","journal-title":"Leukemia"},{"issue":"17","key":"7142_CR94","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","volume":"145","author":"I Mantzaris","year":"2025","unstructured":"Mantzaris I et al (2025) Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study. Blood 145(17):1870\u20131875","journal-title":"Blood"},{"issue":"25","key":"7142_CR95","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39(25):2768\u20132778","journal-title":"J Clin Oncol"},{"issue":"7","key":"7142_CR96","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40265-025-02194-w","volume":"85","author":"L Pagano","year":"2025","unstructured":"Pagano L et al (2025) The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety. Drugs 85(7):855\u2013866","journal-title":"Drugs"},{"issue":"26","key":"7142_CR97","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36(26):2684\u20132692","journal-title":"J Clin Oncol"},{"issue":"7","key":"7142_CR98","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE et al (2021) CPX-351 versus 7\u2009+\u20093 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8(7):e481\u2013e491","journal-title":"Lancet Haematol"},{"issue":"2","key":"7142_CR99","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H et al (2021) Acute myeloid leukemia: current progress and future directions. Blood cancer J 11(2):41","journal-title":"Blood cancer J"},{"issue":"23","key":"7142_CR100","first-page":"3441","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF et al (2014) Differential impact of allelic ratio and insertion site in FLT3-ITD\u2013positive AML with respect to allogeneic transplantation. Blood. J Am Soc Hematol 124(23):3441\u20133449","journal-title":"J Am Soc Hematol"},{"issue":"14","key":"7142_CR101","first-page":"2734","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M et al (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood J Am Soc Hematol 121(14):2734\u20132738","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"7142_CR102","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464","journal-title":"N Engl J Med"},{"issue":"10388","key":"7142_CR103","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP et al (2023) Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10388):1571\u20131583","journal-title":"Lancet"},{"issue":"16","key":"7142_CR104","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P et al (2022) Ivosidenib and Azacitidine in <\u2009i>IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med 386(16):1519\u20131531","journal-title":"N Engl J Med"},{"issue":"7","key":"7142_CR105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","volume":"133","author":"EM Stein","year":"2019","unstructured":"Stein EM et al (2019) Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133(7):676\u2013687","journal-title":"Blood"},{"issue":"13","key":"7142_CR106","first-page":"1792","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein EM et al (2021) Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood J Am Soc Hematol 137(13):1792\u20131803","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"7142_CR107","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC et al (2021) Therapeutic implications of menin inhibition in acute leukemias. Leukemia 35(9):2482\u20132495","journal-title":"Leukemia"},{"issue":"11","key":"7142_CR108","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2165\/00002512-200522110-00004","volume":"22","author":"K Lang","year":"2005","unstructured":"Lang K et al (2005) Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 22(11):943\u2013955","journal-title":"Drugs Aging"},{"issue":"3","key":"7142_CR109","first-page":"291","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood. J Am Soc Hematol 126(3):291\u2013299","journal-title":"J Am Soc Hematol"},{"issue":"21","key":"7142_CR110","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677","journal-title":"J Clin Oncol"},{"issue":"2","key":"7142_CR111","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"O Faustine","year":"2022","unstructured":"Faustine O, Kunhwa K, Marina K (2022) Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist 5(2):380\u2013400","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"7142_CR112","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"key":"7142_CR113","doi-asserted-by":"crossref","unstructured":"Pratz KW et al (2022) Long-term follow-up of the phase 3 viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. American Society of Hematology Washington, DC","DOI":"10.1182\/blood-2022-158518"},{"issue":"13","key":"7142_CR114","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ et al (2024) Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 42(13):1499\u20131508","journal-title":"J Clin Oncol"},{"issue":"4","key":"7142_CR115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA et al (2023) A phase Ib\/II study of ivosidenib with venetoclax\u00b1azacitidine in IDH1-mutated myeloid malignancies. Blood cancer discovery 4(4):276\u2013293","journal-title":"Blood cancer discovery"},{"issue":"21","key":"7142_CR116","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2016.67.6395","volume":"34","author":"CS Hourigan","year":"2016","unstructured":"Hourigan CS et al (2016) When the Minimal Becomes Measurable. J Clin Oncol 34(21):2557\u20132558","journal-title":"J Clin Oncol"},{"issue":"5","key":"7142_CR117","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA et al (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102(5):865\u2013873","journal-title":"Haematologica"},{"issue":"4","key":"7142_CR118","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D et al (2016) Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol 34(4):329\u2013336","journal-title":"J Clin Oncol"},{"key":"7142_CR119","doi-asserted-by":"crossref","unstructured":"Parks K et al (2024) Post-transplant maintenance therapy in acute myeloid leukemia. Cancers 16(11):2015","DOI":"10.3390\/cancers16112015"},{"issue":"8","key":"7142_CR120","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L et al (2023) Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with <\u2009em>FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10(8):e600\u2013e611","journal-title":"Lancet Haematol"},{"issue":"15","key":"7142_CR121","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ et al (2024) Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <\u2009i>FLT3. J Clin Oncol 42(15):1766\u20131775","journal-title":"J Clin Oncol"},{"issue":"22","key":"7142_CR122","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301(22):2349\u20132361","journal-title":"JAMA"},{"issue":"9","key":"7142_CR123","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ajh.26997","volume":"98","author":"A Bazinet","year":"2023","unstructured":"Bazinet A et al (2023) Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383\u20131393","journal-title":"Am J Hematol"},{"issue":"9","key":"7142_CR124","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L et al (2020) Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 21(9):1201\u20131212","journal-title":"Lancet Oncol"},{"issue":"4","key":"7142_CR125","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/S2352-3026(24)00034-6","volume":"11","author":"A Bazinet","year":"2024","unstructured":"Bazinet A et al (2024) Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287\u2013e298","journal-title":"Lancet Haematol"},{"issue":"3","key":"7142_CR126","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG et al (2024) Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol 25(3):388\u2013399","journal-title":"Lancet Oncol"},{"issue":"7","key":"7142_CR127","first-page":"507","volume":"138","author":"R Itzykson","year":"2021","unstructured":"Itzykson R et al (2021) Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. J Am Soc Hematol 138(7):507\u2013519","journal-title":"J Am Soc Hematol"},{"issue":"19","key":"7142_CR128","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.2023022202","volume":"143","author":"H Gu","year":"2024","unstructured":"Gu H et al (2024) PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood 143(19):1965\u20131979","journal-title":"Blood"},{"issue":"2","key":"7142_CR129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ccell.2015.12.011","volume":"29","author":"ER Lechman","year":"2016","unstructured":"Lechman ER et al (2016) miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29(2):214\u2013228","journal-title":"Cancer Cell"},{"issue":"2","key":"7142_CR130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","volume":"13","author":"H-S Zhou","year":"2016","unstructured":"Zhou H-S, Carter BZ, Andreeff M (2016) Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer biology Med 13(2):248\u2013259","journal-title":"Cancer biology Med"},{"issue":"1","key":"7142_CR131","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q et al (2022) Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target therapy 7(1):51","journal-title":"Signal Transduct Target therapy"},{"issue":"7","key":"7142_CR132","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","volume":"35","author":"C Rummelt","year":"2021","unstructured":"Rummelt C et al (2021) Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia 35(7):2017\u20132029","journal-title":"Leukemia"},{"key":"7142_CR133","doi-asserted-by":"crossref","unstructured":"Alati C, Carullo S, Marrapodi MM, et al (2026) Menin inhibition in acute myeloid MLL rearranged leukemias: a new target for precision care. Cancers 18(4):637","DOI":"10.3390\/cancers18040637"},{"issue":"9","key":"7142_CR134","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.trecan.2025.06.002","volume":"11","author":"L Boussi","year":"2025","unstructured":"Boussi L, Cai SF, Stein EM (2025) Advances in menin inhibition in acute myeloid leukemia. Trends Cancer 11(9):889\u2013900","journal-title":"Trends Cancer"},{"issue":"6","key":"7142_CR135","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3390\/jcm15062171","volume":"15","author":"C Stafylidis","year":"2026","unstructured":"Stafylidis C, Diamantopoulos PT (2026) Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies. J Clin Med 15(6):2171","journal-title":"J Clin Med"},{"key":"7142_CR136","doi-asserted-by":"crossref","unstructured":"Song F et al (2025) Targeted therapy in acute myeloid leukemia: resistance and overcoming strategy. Drug Resist Updates 83:101286","DOI":"10.1016\/j.drup.2025.101286"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07142-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:51Z","timestamp":1791673551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07142-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":136,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7142"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07142-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":3,"name":"Ethics","label":"Institutional review board (IRB) statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"416"}}